Legend Biotech
Executive Director, Multiple Myeloma Pipeline Lead
$294K–$387K
Somerset, New Jersey, United States · Director · Full-time · Posted Oct 1, 2026
- Experience
- Minimum of 6 years of clinical development experience in the biopharmaceutical industry and/or academic medicine.
- Education
- MD, MD-PhD, or equivalent medical degree; board certification in hematology or oncology required.
- Visa sponsorship
- Applicants must be authorized to work in the United States; the employer participates in E-Verify.
About the job
Leads clinical development strategy and execution across Legend Biotech’s multiple myeloma pipeline, advancing early- and late-stage programs toward registration and commercialization.
What you'll do
- Set pipeline strategy, prioritization, asset sequencing, and development-stage decision criteria across multiple programs.
- Lead design, execution, oversight, interpretation, and reporting of early clinical studies and contribute to late-stage and registration-enabling development.
- Direct cross-functional teams, regulatory and governance activities, evidence generation, and clinical development personnel.
What they ask for
- MD, MD-PhD, or equivalent medical degree; board certification in hematology or oncology.
- At least 6 years of clinical development experience in biopharmaceutical industry and/or academic medicine, with substantial hematologic malignancy and multiple myeloma experience.
- Demonstrated experience designing and leading early clinical development programs, including first-in-human studies, dose escalation, dose expansion, dose selection, safety monitoring, and proof-of-concept.
- Ability to travel up to 15–20% of the time.
Nice to have
- Multiple myeloma clinical development experience across relapsed/refractory and earlier-line settings.
- Experience with innovative therapies such as cell therapy, CAR-T, in vivo cell therapy, T-cell engagers, bispecific antibodies, antibody-drug conjugates, or protein degraders.
Pay
$294,483 — $386,511 USD (base pay)
Model-written summary · the original posting is authoritative